180 Life Sciences: Deliberately Seeking Serendipity

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Normalcy is something we can now only recall, though we may also be seeing the small silhouette of a returning ship on the horizon.

180 Life Sciences (180 LS) could seem like a return to the normalcy of the mid-1980s, when almost every pharma company was diminutive, tightly focused on an exclusive area, and deeply involved in its own scientific and market space. When companies took risks, it was more out of confidence than derring-do because they could often turn in-house to the very leadership and knowledge that had created those markets in the first place. The difference nowadays appears in the exceptional case of 180 LS, where veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities. Within its focus on three areas of inflammatory diseases, each one matching one of its therapeutic platforms, 180 maintains an openness to unforeseen product opportunities.